Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more
Protara Therapeutics Inc (TARA) - Total Liabilities
Latest total liabilities as of September 2025: $12.35 Million USD
Based on the latest financial reports, Protara Therapeutics Inc (TARA) has total liabilities worth $12.35 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Protara Therapeutics Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Protara Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Protara Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Protara Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vizionfocus Inc.
TW:4771
|
Taiwan | NT$2.44 Billion |
|
John Mattson Fastighetsforetagen AB
ST:JOMA
|
Sweden | Skr8.78 Billion |
|
Boryung Pharm
KO:003850
|
Korea | ₩537.67 Billion |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
USA | $102.49 Million |
|
Curacle Co. Ltd.
KQ:365270
|
Korea | ₩16.67 Billion |
|
NEXCOM International Co Ltd
TWO:8234
|
Taiwan | NT$2.75 Billion |
|
I-PEX Inc.
OTCGREY:DAIKF
|
USA | $34.10 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Protara Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protara Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protara Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Protara Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.32 Million | +34.68% |
| 2023-12-31 | $10.63 Million | -5.12% |
| 2022-12-31 | $11.21 Million | +4.91% |
| 2021-12-31 | $10.68 Million | +172.92% |
| 2020-12-31 | $3.91 Million | +571.36% |
| 2019-12-31 | $583.00K | -81.06% |
| 2018-12-31 | $3.08 Million | -66.69% |
| 2017-12-31 | $9.24 Million | +81.93% |
| 2016-12-31 | $5.08 Million | +22.89% |
| 2015-12-31 | $4.13 Million | +76.78% |
| 2014-12-31 | $2.34 Million | -76.06% |
| 2013-12-31 | $9.77 Million | +135.26% |
| 2012-12-31 | $4.15 Million | -- |